FindTrial
Sign In

A Prospective cross-over randomized controlled trial of protein bound uremic toxin reduction between super high-flux hemodialysis and high-efficiency online hemodiafiltration

A Prospective cross-over randomized controlled trial of protein bound uremic toxin reduction between super high-flux hemodialysis and high-efficiency online hemodiafiltration

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181019001
Enrollment
12
Registered
2018-10-19
Start date
2018-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

albumin lost in dialysate fluid

Interventions

PES 17 D alpha dialyzer hemodialysis,HF80 dialyzer with online HDF
Experimental Device,Active Comparator Device
Super high flux HD,Online HDF

Sponsors

Nipro, Japan
Lead Sponsor
Fresenius
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: • Age between 18 to 90 year&#45;old • ESRD on HD at least 3 months • HD at least 3 times per week and spKt/v > 1.2 • Residual renal function < 100 ml • AVF or AVG that BFR more than 400 ml/min • Appropriated dry weight by BCM • Hemodynamic stability

Exclusion criteria

Exclusion criteria: • Uncorrected heart disease and severe infection • Advance malignancy • Cirrhosis Child Pugh score B to C • Pregnancy • Contraindication for anticoagulant • refuse inform consent

Design outcomes

Primary

MeasureTime frame
Indoxyl sulphate reduction ratio end of the study percentage—

Secondary

MeasureTime frame
beta2 microglobulin reduction ratio end of the study percentage—

Countries

Thailand

Contacts

Public ContactKhajohn Tiranathanagul

Nephrology division King Chulalongkorn Memorial Hospital

khajohn_t@hotmail.com0865245990

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026